Discovery and optimization of a new class of pyruvate kinase inhibitors as potential therapeutics for the treatment of methicillin-resistant Staphylococcus aureus infections

被引:36
|
作者
Kumar, Nag S. [1 ]
Dullaghan, Edie M. [2 ]
Finlay, B. Brett [3 ,4 ]
Gong, Huansheng [4 ]
Reiner, Neil E. [4 ,5 ]
Selvam, J. Jon Paul [1 ]
Thorson, Lisa M. [4 ]
Campbell, Sara [2 ]
Vitko, Nicholas [6 ]
Richardson, Anthony R. [6 ]
Zoraghi, Roya [4 ]
Young, Robert N. [1 ]
机构
[1] Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada
[2] Ctr Drug Res & Dev, Vancouver, BC, Canada
[3] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada
[4] Univ British Columbia, Dept Med, Div Infect Dis, Vancouver, BC, Canada
[5] Univ British Columbia, Michael Smith Labs, Dept Microbiol & Immunol, Vancouver, BC V5Z 1M9, Canada
[6] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
基金
加拿大自然科学与工程研究理事会;
关键词
Antibacterial; MRSA; Pyruvate kinase; Bis-indole; EFFLUX;
D O I
10.1016/j.bmc.2014.01.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A novel series of bis-indoles derived from naturally occurring marine alkaloid 4 were synthesized and evaluated as inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase (PK). PK is not only critical for bacterial survival which would make it a target for development of novel antibiotics, but it is reported to be one of the most highly connected 'hub proteins' in MRSA, and thus should be very sensitive to mutations and making it difficult for the bacteria to develop resistance. From the co-crystal structure of cis-3-4-dihydrohamacanthin B (4) bound to S. aureus PK we were able to identify the pharmacophore needed for activity. Consequently, we prepared simple direct linked bis-indoles such as 10b that have similar anti-MRSA activity as compound 4. Structure-activity relationship (SAR) studies were carried out on 10b and led us to discover more potent compounds such as 10c, 10d, 10k and 10m with enzyme inhibiting activities in the low nanomolar range that effectively inhibited the bacteria growth in culture with minimum inhibitory concentrations (MIC) for MRSA as low as 0.5 mu g/ml. Some potent PK inhibitors, such as 10b, exhibited attenuated antibacterial activity and were found to be substrates for an efflux mechanism in S. aureus. Studies comparing a wild type S. aureus with a construct (S. aureus LAC Delta pyk::ErmR) that lacks PK activity confirmed that bactericidal activity of 10d was PK-dependant. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1708 / 1725
页数:18
相关论文
共 50 条
  • [11] Role of Berberine in the Treatment of Methicillin-Resistant Staphylococcus aureus Infections
    Chu, Ming
    Zhang, Ming-bo
    Liu, Yan-chen
    Kang, Jia-rui
    Chu, Zheng-yun
    Yin, Kai-lin
    Ding, Ling-yu
    Ding, Ran
    Xiao, Rong-xin
    Yin, Yi-nan
    Liu, Xiao-yan
    Wang, Yue-dan
    SCIENTIFIC REPORTS, 2016, 6
  • [12] Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus
    Mensa, J.
    Barberan, J.
    Llinares, P.
    Picazo, J. J.
    Bouza, E.
    Alvarez Lerma, F.
    Borges, M.
    Serrano, R.
    Leon, C.
    Guirao, X.
    Arias, J.
    Carreras, E.
    Sanz, M. A.
    Garcia Rodriguez, J. A.
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2008, 21 (04) : 234 - 258
  • [13] New cephalosporin as an alternative for treatment of infections by methicillin-resistant Staphylococcus aureus (MRSA)
    Batista, Bruna Gerardon
    Rauber, Janine de Melo
    Bruschi, Jaine Stypulsowski
    d'Azevedo, Pedro Alves
    REVISTA DE EPIDEMIOLOGIA E CONTROLE DE INFECCAO, 2015, 5 (02): : 94 - 99
  • [14] Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections
    Micek, Scott T.
    CLINICAL INFECTIOUS DISEASES, 2007, 45 : S184 - S190
  • [15] Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children
    Kaplan, SL
    Afghani, B
    Lopez, P
    Wu, EB
    Fleishaker, D
    Edge-Padbury, B
    Naberhuis-Stehouwer, S
    Bruss, JB
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (09) : S176 - S183
  • [16] TREATMENT OF INFECTIONS DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS
    WATANAKUNAKORN, C
    ANNALS OF INTERNAL MEDICINE, 1982, 97 (03) : 376 - 378
  • [18] Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections
    Loffler, Cindy A.
    MacDougo, Conan
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2007, 5 (06) : 961 - 981
  • [19] TREATMENT OF INFECTIONS DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS
    WALDVOGEL, FA
    JOURNAL OF HOSPITAL INFECTION, 1986, 7 : 37 - 46
  • [20] Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children
    Frank, AL
    Marcinak, JF
    Mangat, PD
    Tjhio, JT
    Kelkar, S
    Schreckenberger, PC
    Quinn, JP
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (06) : 530 - 534